[Form 4] Aptevo Therapeutics Inc Insider Trading Activity
Aptevo Therapeutics director Barbara Lopez Kunz was granted 7,200 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock and the award vests in full on the first anniversary of the grant date. The reported position is held directly and the RSUs are recorded with a $0 per-share conversion price as described in the filing.
Alla direttrice di Aptevo Therapeutics, Barbara Lopez Kunz, sono state assegnate 7.200 Restricted Stock Units (RSU) il 08/06/2025. Ogni RSU si converte in azioni ordinarie in rapporto uno a uno e l'intero premio matura il primo anniversario della data di assegnazione. La posizione segnalata 猫 detenuta direttamente e le RSU sono registrate con un prezzo di conversione per azione pari a $0, come indicato nel deposito.
A la directora de Aptevo Therapeutics, Barbara Lopez Kunz, se le otorgaron 7.200 Unidades de Acciones Restringidas (RSU) el 08/06/2025. Cada RSU se convierte en acciones ordinarias a raz贸n de una por una y la concesi贸n se adquiere en su totalidad al primer aniversario de la fecha de otorgamiento. La posici贸n declarada se mantiene directamente y las RSU se registran con un precio de conversi贸n por acci贸n de $0, seg煤n consta en la presentaci贸n.
Aptevo Therapeutics鞚� 鞚挫偓 Barbara Lopez Kunz電� 08/06/2025鞐� 7,200臧滌潣 鞝滍暅攵� 欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅橂┌, 攵�鞐澕搿滊秬韯� 1欤茧厔鞚检棎 鞝勲秬 旆摑霅╇媹雼�. 氤搓碃霅� 歆�攵勳潃 歆侅为 氤挫湢 欷戩澊氅�, 鞝滌稖 靹滊鞐� 靹る獏霅� 氚旍檧 臧欖澊 RSU電� 欤茧嫻 鞝勴櫂 臧�瓴╈澊 $0搿� 旮半霅橃柎 鞛堨姷雼堧嫟.
La directrice d'Aptevo Therapeutics, Barbara Lopez Kunz, s'est vu attribuer 7 200 unit茅s d'actions restreintes (RSU) le 08/06/2025. Chaque RSU se convertit en actions ordinaires au taux d'une pour une et l'attribution devient enti猫rement acquise au premier anniversaire de la date d'octroi. La position d茅clar茅e est d茅tenue directement et les RSU sont inscrites avec un prix de conversion de 0 $ par action, comme indiqu茅 dans le d茅p么t.
Die Direktorin von Aptevo Therapeutics, Barbara Lopez Kunz, erhielt am 08/06/2025 7.200 Restricted Stock Units (RSUs). Jede RSU wandelt sich eins zu eins in Stammaktien um und die Zuteilung wird am ersten Jahrestag des Gew盲hrungsdatums vollst盲ndig f盲llig. Die gemeldete Position wird direkt gehalten, und die RSUs sind mit einem Umwandlungspreis von $0 pro Aktie, wie in der Einreichung beschrieben, verbucht.
- None.
- None.
Insights
TL;DR: Routine director equity grant鈥�7,200 RSUs vesting after one year, aligning long-term interests but not an immediate equity transfer.
The filing documents a standard restrictive equity award to a director rather than an open-market purchase or sale. The RSUs convert on a one-for-one basis to common stock and vest in full on the first anniversary of the grant, which means no immediate increase in outstanding shares until vesting occurs. Ownership is recorded as direct, and the RSUs show a $0 conversion price consistent with typical restricted awards. From a governance viewpoint, this is a common practice to align director incentives with shareholders without immediate dilution.
TL;DR: Non-cash compensation grant to a director鈥�7,200 RSUs; materiality depends on company share count, but filing itself is routine.
The transaction code indicates an acquisition of derivative securities in the form of RSUs. The filing specifies 7,200 RSUs underlying 7,200 common shares upon conversion and lists the transaction date as 08/06/2025. Because the award vests one year after grant, there is no immediate transfer of common shares reported here. The $0 listed for the RSU conversion reflects the standard administrative treatment of restricted awards. This is a routine insider compensation disclosure rather than a market-moving sale or purchase.
Alla direttrice di Aptevo Therapeutics, Barbara Lopez Kunz, sono state assegnate 7.200 Restricted Stock Units (RSU) il 08/06/2025. Ogni RSU si converte in azioni ordinarie in rapporto uno a uno e l'intero premio matura il primo anniversario della data di assegnazione. La posizione segnalata 猫 detenuta direttamente e le RSU sono registrate con un prezzo di conversione per azione pari a $0, come indicato nel deposito.
A la directora de Aptevo Therapeutics, Barbara Lopez Kunz, se le otorgaron 7.200 Unidades de Acciones Restringidas (RSU) el 08/06/2025. Cada RSU se convierte en acciones ordinarias a raz贸n de una por una y la concesi贸n se adquiere en su totalidad al primer aniversario de la fecha de otorgamiento. La posici贸n declarada se mantiene directamente y las RSU se registran con un precio de conversi贸n por acci贸n de $0, seg煤n consta en la presentaci贸n.
Aptevo Therapeutics鞚� 鞚挫偓 Barbara Lopez Kunz電� 08/06/2025鞐� 7,200臧滌潣 鞝滍暅攵� 欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅橂┌, 攵�鞐澕搿滊秬韯� 1欤茧厔鞚检棎 鞝勲秬 旆摑霅╇媹雼�. 氤搓碃霅� 歆�攵勳潃 歆侅为 氤挫湢 欷戩澊氅�, 鞝滌稖 靹滊鞐� 靹る獏霅� 氚旍檧 臧欖澊 RSU電� 欤茧嫻 鞝勴櫂 臧�瓴╈澊 $0搿� 旮半霅橃柎 鞛堨姷雼堧嫟.
La directrice d'Aptevo Therapeutics, Barbara Lopez Kunz, s'est vu attribuer 7 200 unit茅s d'actions restreintes (RSU) le 08/06/2025. Chaque RSU se convertit en actions ordinaires au taux d'une pour une et l'attribution devient enti猫rement acquise au premier anniversaire de la date d'octroi. La position d茅clar茅e est d茅tenue directement et les RSU sont inscrites avec un prix de conversion de 0 $ par action, comme indiqu茅 dans le d茅p么t.
Die Direktorin von Aptevo Therapeutics, Barbara Lopez Kunz, erhielt am 08/06/2025 7.200 Restricted Stock Units (RSUs). Jede RSU wandelt sich eins zu eins in Stammaktien um und die Zuteilung wird am ersten Jahrestag des Gew盲hrungsdatums vollst盲ndig f盲llig. Die gemeldete Position wird direkt gehalten, und die RSUs sind mit einem Umwandlungspreis von $0 pro Aktie, wie in der Einreichung beschrieben, verbucht.
FAQ
What did Aptevo (APVO) disclose in this Form 4 filing?
Do the RSUs reported for APVO immediately increase common shares outstanding?
What is the conversion price or cost reported for the RSUs in the APVO filing?
How is the beneficial ownership described for the reported RSUs in the APVO Form 4?
When will the reported RSUs for APVO become exercisable or convertible?
